​

Black Diamond Therapeutics (BDTX) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Black Diamond Therapeutics Revenue Highlights

00

Main Segment (Y)

Reportable Segment

Black Diamond Therapeutics Revenue by Period

Black Diamond Therapeutics Revenue by Year

DateRevenueChange
2025-12-31-100.00%
2024-12-31-100.00%
2023-12-31-100.00%
2022-12-31-100.00%
2021-12-31-100.00%
2020-12-31-100.00%
2019-12-31-100.00%
2018-12-31-100.00%
2017-12-31--

Black Diamond Therapeutics generated - in revenue during NA 2025, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.

Black Diamond Therapeutics Revenue by Quarter

DateRevenueChange
2025-09-30-100.00%
2025-06-30--100.00%
2025-03-31$70.00M13465.89%
2024-12-31$516.00K100.00%
2024-09-30-100.00%
2024-06-30-100.00%
2024-03-31--100.00%
2023-12-31$4.89M100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31-100.00%
2022-12-31-100.00%
2022-09-30-100.00%
2022-06-30-100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31--

Black Diamond Therapeutics generated - in revenue during Q3 2025, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.

Black Diamond Therapeutics Revenue Breakdown

Black Diamond Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 25
Reportable Segment$70.00M

Black Diamond Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 25: Reportable Segment (100.00%).

Quarterly Revenue by Product

Product/ServiceDec 25Mar 25
Reportable Segment-$70.00M

Black Diamond Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
ENTAEnanta Pharmaceuticals$65.32M$18.61M
FENCFennec Pharmaceuticals$45.42M$9.65M
FHTXFoghorn Therapeutics$30.91M$8.15M
IVAInventiva$17.48M$2.73M
ABEOAbeona Therapeutics$5.82M-
AVTXAvalo Therapeutics$59.00K-
IMRXImmuneering--
BDTXBlack Diamond Therapeutics--
AARDAardvark Therapeutics--
CRBUCaribou Biosciences--
TNYATenaya Therapeutics--

BDTX Revenue FAQ

What is Black Diamond Therapeutics’s yearly revenue?

Black Diamond Therapeutics's yearly revenue for 2025 was $0, representing an increase of 100.00% compared to 2024. The company's yearly revenue for 2024 was $0, representing an increase of 100.00% compared to 2023. BDTX's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022.

What is Black Diamond Therapeutics’s quarterly revenue?

Black Diamond Therapeutics's quarterly revenue for Q3 2025 was $0, a 100.00% increase from the previous quarter (Q2 2025), and a 0% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $0, a -100.00% decrease from the previous quarter (Q1 2025), and a 0% increase year-over-year (Q2 2024). BDTX's quarterly revenue for Q1 2025 was $70M, a 13465.89% increase from the previous quarter (Q4 2024), and a 0% increase year-over-year (Q1 2024).

What is Black Diamond Therapeutics’s revenue growth rate?

Black Diamond Therapeutics's revenue growth rate for the last 3 years (2023-2025) was 0%, and for the last 5 years (2021-2025) was 0%.

What are Black Diamond Therapeutics’s revenue streams?

Black Diamond Therapeutics's revenue streams in c 25 are Reportable Segment

What is Black Diamond Therapeutics’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Black Diamond Therapeutics was Reportable Segment. This segment made a revenue of $70M, representing 100.00% of the company's total revenue.